Tirzepatide
Mounjaro (type 2 diabetes) · Zepbound (weight management)
Tirzepatide Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 2 diabetes mellitus — glycemic control (Mounjaro) | Adults; pediatric patients ≥10 years | Adjunctive to diet & exercise | FDA Approved |
| Chronic weight management (Zepbound) | Adults with BMI ≥30, or ≥27 with ≥1 weight-related comorbidity | Adjunctive to reduced-calorie diet & increased physical activity | FDA Approved |
| Obstructive sleep apnea — moderate-to-severe (Zepbound) | Adults with obesity | Adjunctive to reduced-calorie diet & increased physical activity | FDA Approved |
Tirzepatide is the first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, sometimes called a “twincretin.” It was initially approved in May 2022 as Mounjaro for type 2 diabetes and subsequently as Zepbound (November 2023) for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The pediatric indication for Mounjaro (age ≥10 years) was added in December 2025. Tirzepatide is not indicated for type 1 diabetes mellitus and has not been studied in patients with a history of pancreatitis. Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.
Non-alcoholic steatohepatitis (NASH/MASH): The SYNERGY-NASH trial demonstrated significant resolution of steatohepatitis with tirzepatide. Evidence quality: High (phase 2 RCT).
Heart failure with preserved ejection fraction (HFpEF) and obesity: The SUMMIT trial showed improvements in heart failure symptoms and exercise capacity. Evidence quality: High (phase 3 RCT).
Polycystic ovary syndrome (PCOS): Preliminary data suggest improvements in metabolic and reproductive parameters. Evidence quality: Low.
Tirzepatide Dosing
Type 2 Diabetes (Mounjaro) — Adults & Pediatric ≥10 Years
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — monotherapy or add-on to oral agents | 2.5 mg SC weekly | 5–15 mg SC weekly | 15 mg/week | 2.5 mg is for initiation only (not intended for glycemic control); increase to 5 mg after 4 weeks Titrate in 2.5 mg increments every ≥4 weeks based on response |
| T2DM — add-on to sulfonylurea | 2.5 mg SC weekly | 5–15 mg SC weekly | 15 mg/week | Consider reducing SFU dose to mitigate hypoglycemia risk Hypoglycemia <54 mg/dL occurred in 10–14% with SFU in SURPASS-4 |
| T2DM — add-on to basal insulin ± metformin | 2.5 mg SC weekly | 5–15 mg SC weekly | 15 mg/week | Evaluate insulin dose when initiating; may need reduction Never mix tirzepatide and insulin in same syringe; inject in same region but not adjacent |
Chronic Weight Management (Zepbound) — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidity | 2.5 mg SC weekly | 5–15 mg SC weekly | 15 mg/week | Same titration as T2DM; target maximum tolerated dose for best weight outcomes In SURMOUNT-1, 15 mg achieved ~20.9% total weight loss at 72 weeks |
| Moderate-to-severe OSA with obesity | 2.5 mg SC weekly | 10–15 mg SC weekly | 15 mg/week | Target dose for OSA benefit was 10–15 mg in clinical trials AHI reductions of ~50% at higher doses |
Missed Dose Guidance
Administer as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip the missed dose and resume on the regular scheduled day. The day of weekly injection may be changed as long as at least 3 days (72 hours) separate two doses.
The slow titration schedule (2.5 mg increments every 4 weeks) is the primary mitigation strategy for gastrointestinal tolerability. Rushing escalation is the most common cause of treatment discontinuation. In clinical trials, the majority of GI adverse events occurred during dose escalation and decreased at steady maintenance doses. Consider pausing at intermediate doses (7.5 mg or 12.5 mg) if a patient tolerates the current dose well but reports significant GI symptoms after each increase.
Pharmacology of Tirzepatide
Mechanism of Action
Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates both the GIP and GLP-1 receptors, making it the first approved dual incretin receptor agonist. Its primary structure is based on the GIP sequence, with modifications enabling GLP-1 receptor co-agonism. A C20 fatty diacid moiety is attached via a linker to facilitate high-affinity binding to albumin, which extends the plasma half-life to approximately 5 days and enables once-weekly dosing. At the GIP receptor, tirzepatide has comparable affinity to native GIP. At the GLP-1 receptor, its affinity is approximately 5-fold lower than native GLP-1, but this is offset by sustained exposure from albumin binding. The combined dual-receptor activation produces enhanced glucose-dependent insulin secretion, suppression of inappropriately elevated glucagon, slowed gastric emptying, and centrally mediated appetite reduction. The GIP receptor component contributes additional effects on lipid metabolism in adipose tissue and may help preserve lean mass during weight loss, distinguishing tirzepatide from pure GLP-1 receptor agonists.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ~80% (SC); Tmax 8–72 h; dose-proportional PK across 2.5–15 mg | Injection site (abdomen, thigh, arm) does not affect exposure; any time of day, with or without meals |
| Distribution | Vd ~10.3 L (steady state); 99% protein bound (albumin) | Small volume of distribution consistent with mainly intravascular distribution; albumin binding drives long half-life |
| Metabolism | Proteolytic cleavage of peptide backbone; β-oxidation of C20 fatty diacid; amide hydrolysis; no CYP involvement | No hepatic CYP-mediated metabolism; hepatic impairment does not require dose adjustment; minimal classical drug-drug interaction risk |
| Elimination | t½ ~5 days; CL 0.061 L/h; urine ~66%, feces ~33% (as metabolites); no intact drug in excreta | Steady state reached in ~4 weeks; renal impairment (any degree) does not meaningfully alter exposure |
Side Effects of Tirzepatide
| Adverse Effect | Incidence (15 mg) | Clinical Note |
|---|---|---|
| Nausea | 18% (vs 4% placebo) | Dose-dependent; most common adverse reaction; typically peaks during dose escalation and attenuates at stable dose |
| Diarrhea | 17% (vs 9% placebo) | Usually mild to moderate; monitor for dehydration, particularly in patients on diuretics or with renal impairment |
| Decreased appetite | 11% (vs 1% placebo) | Contributes to weight loss effect; generally beneficial in T2DM with obesity but monitor nutritional status |
| Adverse Effect | Incidence (15 mg) | Clinical Note |
|---|---|---|
| Vomiting | 9% (vs 2% placebo) | Usually occurs during dose escalation; if severe or persistent, assess for dehydration and hold until resolved |
| Constipation | 7% (vs 1% placebo) | Related to slowed gastric emptying; encourage adequate hydration and fibre intake |
| Dyspepsia | 5% (vs 3% placebo) | Part of the broader GI profile; consider smaller, more frequent meals |
| Abdominal pain | 5% (vs 4% placebo) | Evaluate for pancreatitis if severe and persistent, especially if radiating to back |
| Eructation | 3.3% (vs 0.4% placebo) | Generally mild; self-limiting |
| Injection-site reactions | 3.2% (vs 0.4% placebo) | More common in patients who develop anti-tirzepatide antibodies (4.6% vs 0.7% without antibodies) |
| Hypersensitivity reactions | 3.2% (vs 1.7% placebo) | Includes urticaria and eczema; discontinue if severe (anaphylaxis, angioedema) |
| Flatulence | 2.9% (vs 0% placebo) | Usually transient and mild |
| GERD | 1.7% (vs 0.4% placebo) | Consider PPI therapy if symptomatic; evaluate for gastroparesis if severe |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Acute pancreatitis | 0.23 per 100 patient-years | Any time during treatment | Discontinue immediately; initiate supportive care; do not rechallenge |
| Thyroid C-cell tumors | Observed in rodents; unknown in humans | Uncertain | Contraindicated with personal/family history of MTC or MEN 2; counsel on thyroid tumor symptoms |
| Anaphylaxis / angioedema | Rare (postmarketing) | Any time | Discontinue permanently; emergency treatment |
| Acute kidney injury | Rare (postmarketing) | Usually with GI-mediated dehydration | Monitor renal function; ensure adequate hydration; withhold during severe GI illness |
| Acute gallbladder disease | 0.6% (vs 0% placebo) | Any time; may relate to rapid weight loss | Gallbladder imaging if cholelithiasis/cholecystitis suspected |
| Severe GI adverse reactions | 0.4–1.3% (dose-dependent) | Usually during dose escalation | Assess hydration and renal function; consider holding dose until resolved |
| Diabetic retinopathy complications | Risk with rapid glucose improvement | Early months of treatment | Monitor patients with pre-existing retinopathy for progression; not studied in NPDR requiring acute therapy, PDR, or DME |
| Pulmonary aspiration (peri-operative) | Rare (postmarketing) | During general anesthesia / deep sedation | Inform surgical team; consider withholding pre-operatively |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Nausea | 1–3% | Most withdrawals occur during dose escalation phase |
| Diarrhea | 0.5–1.5% | Higher at 10 and 15 mg doses |
| Vomiting | 0.5–1.5% | Frequently co-occurs with nausea |
In placebo-controlled trials, tirzepatide increased mean heart rate by 2–4 beats per minute versus 1 bpm with placebo. Sinus tachycardia with a concurrent increase from baseline of ≥15 bpm was observed in 4.6% (5 mg), 5.9% (10 mg), and 10% (15 mg) versus 4.3% with placebo. The clinical relevance of these heart rate increases is uncertain but warrants attention in patients with pre-existing tachyarrhythmias.
Tirzepatide Drug Interactions
Tirzepatide is not metabolized via cytochrome P450 pathways. Its primary interaction mechanism is delayed gastric emptying, which can alter the absorption kinetics of concomitantly administered oral medications. This effect is most pronounced during dose initiation and escalation, when gastric emptying delay is greatest.
Monitoring for Tirzepatide
- HbA1cBaseline, 3 months, then every 3–6 months
RoutineExpected reduction of 1.5–2.5% depending on dose and baseline. In SURPASS-2, tirzepatide 15 mg reduced HbA1c by 2.30% vs 1.86% with semaglutide 1 mg. Consider alternative therapy if inadequate response after 3–6 months at maximum tolerated dose. - Body WeightEvery visit
RoutineWeight loss of 5–12 kg at 40 weeks is typical at 5–15 mg doses. In obesity indication, losses of 15–22% body weight at 72 weeks. Monitor for excessive weight loss in elderly or nutritionally vulnerable patients. - Blood GlucoseOngoing self-monitoring
RoutineCritical when combined with SFU or insulin. Hypoglycemia risk is low as monotherapy or with metformin alone (glucose <54 mg/dL: 0% in SURPASS-1). - Renal FunctionBaseline; during GI illness
Trigger-basedAlthough no dose adjustment is needed for renal impairment, monitor serum creatinine/eGFR if patients experience severe nausea, vomiting, or diarrhea causing dehydration. - GI TolerabilityEach dose escalation visit
RoutineAssess nausea, vomiting, diarrhea severity at each dose escalation. Most GI events are transient and occur during titration. If intolerable, consider remaining at current dose rather than escalating. - Pancreatitis SignsOngoing clinical vigilance
Trigger-basedNote: tirzepatide increases serum pancreatic amylase (33–38%) and lipase (31–42%); routine screening is not recommended. Evaluate clinically if persistent severe abdominal pain develops. - Diabetic RetinopathyBaseline fundoscopy; periodically in at-risk patients
Trigger-basedRapid glucose improvement can worsen pre-existing retinopathy. Tirzepatide has not been studied in patients with NPDR requiring acute therapy, PDR, or DME. Monitor patients with known retinopathy. - Heart RatePeriodically
RoutineMean increase of 2–4 bpm observed in trials; clinical significance uncertain. Exercise increased vigilance in patients with history of arrhythmias.
Contraindications & Cautions
Absolute Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) — thyroid C-cell tumors observed at clinically relevant exposures in rodent carcinogenicity studies.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — elevated baseline MTC risk makes any additional thyroid C-cell stimulation unacceptable.
- Known serious hypersensitivity to tirzepatide or any excipient — anaphylaxis and angioedema reported; do not rechallenge.
Relative Contraindications (Specialist Input Recommended)
- History of pancreatitis — tirzepatide has not been studied in this population; alternative antidiabetic therapy should be considered.
- Non-proliferative diabetic retinopathy requiring acute therapy, proliferative retinopathy, or diabetic macular edema — rapid glucose improvement can worsen these conditions; close ophthalmologic monitoring required.
- History of anaphylaxis or angioedema with another GLP-1 receptor agonist — cross-reactivity unknown; use with caution and close monitoring.
Use with Caution
- Severe gastroparesis or severe gastrointestinal disease — tirzepatide delays gastric emptying and is associated with significant GI adverse reactions; not recommended with severe gastroparesis.
- Concomitant insulin or insulin secretagogues — increased hypoglycemia risk; reduce dose of secretagogue or insulin at initiation.
- Patients scheduled for elective surgery — gastric emptying delay poses aspiration risk under general anesthesia; inform the anesthesia team.
- Females using oral hormonal contraceptives — delayed gastric emptying may reduce efficacy; switch to non-oral method or add barrier for 4 weeks after initiation and each dose escalation.
In both male and female rats, tirzepatide caused dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant plasma exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. Mounjaro and Zepbound are contraindicated in patients with a personal or family history of MTC and in patients with MEN 2. Counsel all patients on the potential risk and advise them to report a neck mass, dysphagia, dyspnea, or persistent hoarseness. Routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection.
Patient Counselling
Purpose of Therapy
Tirzepatide is a once-weekly injectable medication that works on two natural hormone pathways (GIP and GLP-1) to help lower blood sugar, reduce appetite, and promote weight loss. It is used alongside diet and exercise either to manage type 2 diabetes (Mounjaro) or for chronic weight management (Zepbound). It is not insulin and does not replace insulin.
How to Take
Inject in the abdomen, thigh, or upper arm once weekly on the same day each week, at any time of day, with or without food. Rotate injection sites with each dose. The solution should appear clear and colourless to slightly yellow. You will start on a low dose (2.5 mg) and your prescriber will gradually increase the dose every 4 weeks to help your body adjust and reduce stomach side effects.
Sources
- MOUNJARO (tirzepatide) injection, for subcutaneous use. Full Prescribing Information. Eli Lilly and Company. Revised May 2025. FDA LabelPrimary source for Mounjaro dosing, adverse reactions (Table 1), pharmacokinetics, contraindications, and drug interactions.
- ZEPBOUND (tirzepatide) injection, for subcutaneous use. Full Prescribing Information. Eli Lilly and Company. Revised 2025. FDA LabelSource for the chronic weight management and OSA indications, dosing, and safety data from SURMOUNT trials.
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155. doi:10.1016/S0140-6736(21)01324-6SURPASS-1: Monotherapy vs placebo; HbA1c reduction up to −2.07% and weight loss up to −9.5 kg at 40 weeks.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519SURPASS-2: Head-to-head vs semaglutide 1 mg; tirzepatide was superior for HbA1c (−2.30% vs −1.86%) and weight loss (−11.2 vs −5.7 kg) at 15 mg.
- Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398(10300):583–598. doi:10.1016/S0140-6736(21)01443-4SURPASS-3: vs insulin degludec; superior HbA1c and weight outcomes; included liver fat substudy showing significant hepatic steatosis reduction.
- Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398(10313):1811–1824. doi:10.1016/S0140-6736(21)02188-7SURPASS-4: vs insulin glargine in high CV-risk patients (up to 104 weeks); tirzepatide non-inferior for MACE; key source for SFU-combination hypoglycemia data.
- Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022;327(6):534–545. doi:10.1001/jama.2022.0078SURPASS-5: Add-on to basal insulin ± metformin vs placebo; HbA1c reduction up to −2.34%; key source for hypoglycemia with insulin data.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327–340. doi:10.1056/NEJMoa2206038SURMOUNT-1: Placebo-controlled obesity trial; mean weight loss of 20.9% (treatment-regimen estimand) at 72 weeks with 15 mg; basis for the Zepbound approval.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1). doi:10.2337/dc25-SINTCurrent ADA guidelines positioning dual GIP/GLP-1 RAs alongside GLP-1 RAs as preferred agents in T2DM with obesity, CV disease, or CKD.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034ADA/EASD consensus positioning incretin-based therapies early in the treatment algorithm.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009Discovery-to-proof-of-concept paper for tirzepatide; describes the rationale for dual incretin agonism and early PK/PD characterization.
- Schneck KB, Gao W, Engel SS, et al. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol. 2024;13(4):616–627. doi:10.1002/psp4.13099Population PK model from 19 pooled studies; source for t½ ~5 days, bioavailability ~80%, and covariate analysis showing no dose adjustment needed by demographics.
- Urva S, Quinlan T, Engel SS, et al. Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys. Drug Metab Dispos. 2024;52(12):1371–1381. doi:10.1124/dmd.124.001859Radiolabeled ADME study confirming primary elimination via urine (~66%) and feces (~33%) as metabolites; no intact drug in excreta.